Definium Therapeutics (DFTX) Profit After Tax (2019 - 2026)
Definium Therapeutics (DFTX) reported Profit After Tax of -$77.1 million for Q1 2026, down 230.21% year-over-year from $59.2 million in Q1 2025, and down 52.86% quarter-over-quarter from -$50.4 million in Q4 2025.
Definium Therapeutics (DFTX) Profit After Tax (2019 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 7 years of Profit After Tax data on file, last reported at -$77.1 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$77.1 million, down 230.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$237.5 million (down 206.01% YoY), and the FY2025 annual result was -$183.8 million, down 69.12% from the prior year.
- Profit After Tax fell to -$77.1 million in Q1 2026 per DFTX's latest filing, from -$50.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$4.9 million in Q4 2022 and troughed at -$77.1 million in Q1 2026.
- A 5-year average of -$30.7 million and a median of -$23.9 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 79.9% in 2024, then sank 630.17% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$4.9 million in 2022, then plunged by 386.72% to -$23.9 million in 2023, then plunged by 45.58% to -$34.7 million in 2024, then slumped by 45.18% to -$50.4 million in 2025, then tumbled by 52.86% to -$77.1 million in 2026.
- Business Quant data shows DFTX's Profit After Tax at -$77.1 million in Q1 2026, -$50.4 million in Q4 2025, and -$67.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - | -77.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -77.10 Mn |
| Dec 31, 2025 | -50.44 Mn |
| Sep 30, 2025 | -67.27 Mn |
| Jun 30, 2025 | -42.74 Mn |
| Mar 31, 2025 | -23.35 Mn |
| Dec 31, 2024 | -34.74 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | -5.85 Mn |
| Mar 31, 2024 | -54.40 Mn |
| Dec 31, 2023 | -23.86 Mn |
| Sep 30, 2023 | -17.92 Mn |
| Jun 30, 2023 | -29.13 Mn |
| Mar 31, 2023 | -24.82 Mn |
| Dec 31, 2022 | -4.90 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.45 Mn |
| Dec 31, 2021 | -16.83 Mn |
| Sep 30, 2021 | -17.20 Mn |
| Jun 30, 2021 | -45.25 Mn |